Benzoic Acid

Benzoic Acid

SCHEMBL3495871

CN1C(C)(C)CC(Nc2nc(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)c(C(F)(F)F)c3)ncc2F)CC1(C)C.O=C(O)c1ccccc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D

The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.44
MTOR P42345 3/20 0.43
PIM1 P11309 1/20 0.42
CDK4 P11802 1/20 0.42
CCND3 P30281 1/20 0.42
GSK3B P49841 1/20 0.42
SYK P43405 5/20 0.42
ALK Q9UM73 4/20 0.42
KDR P35968 3/20 0.42
JAK2 O60674 2/20 0.42
JAK3 P52333 2/20 0.42
EGFR P00533 2/20 0.42
PRKCQ Q04759 2/20 0.42
FLT3 P36888 2/20 0.42
BTK Q06187 2/20 0.42
CDK2 P24941 2/20 0.42
RET P07949 2/20 0.42
CDC7 O00311 1/20 0.42
PLK4 O00444 1/20 0.42
CHEK1 O14757 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1741976 0.93 BRD4 (0.48) BRD4PIM1CDK4CCND3GSK3B
SCHEMBL3496271 0.88 ALK (0.47) BRD4MTORSYKALKKDR
SCHEMBL3496005 0.87 PRKCQ (0.46) BRD4CDK4CCND3SYKALK
SCHEMBL1743374 0.87 BRD4 (0.49) BRD4SYKALKJAK2JAK3
SCHEMBL1743504 0.86 BRD4 (0.48) BRD4PIM1CDK4CCND3GSK3B
SCHEMBL13268479 0.86 BRD4 (0.55) BRD4PIM1CDK4CCND3GSK3B
SCHEMBL3496272 0.86 SYK (0.59) MTORSYKJAK2JAK3FLT3
SCHEMBL13248983 0.85 BRD4 (0.46) BRD4MTORPIM1CDK4CCND3
SCHEMBL13248962 0.85 BRD4 (0.47) BRD4MTORPIM1CDK4CCND3
SCHEMBL1743509 0.84 BRD4 (0.46) BRD4MTORCDK4SYKALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ BRD4 1173/4885MTOR 220/4885PIM1 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.